Ümit Mercan, Ogün Erşen, Ali Ekrem Ünal, Cemil Yüksel

Does hyperthermic intraperitoneal chemotherapy influencethe rate of infective complications and change the patternof infectious agents in patients undergoing cytoreductivesurgery for peritoneal carcinomatosis?

Aim: When CRS, in which complex surgical procedures are applied combined with HIPEC in which high dose cytotoxic agents areapplied, many serious postoperative complications, especially infection-related complications, may develop in the patient groupwith peritoneal carcinomatosis whose general condition is impaired. In this study, it was aimed to investigate the effect of HIPECapplication after SRC on infection rates and microbial agent spectrum alone. Materials and Methods: Between January 2012 and January 2020, one thousand six hundreds forty eight patients diagnosed withperitoneal carcinomatosis were scanned from hospital database and two hundred thirty-five eligible patients were included in thestudy. Demographic and clinical data, perioperative results and culture results were analyzed by grouping the patients as HIPEC andnon-HIPEC. Results : It has been found that the incidence of surgical site infections was significantly higher in HIPEC group. (23.6%vs11.5%p=0.011). When the culture results were analyzed. The number of patients with E.coli (13.7% vs 5.7% p = 0.001), Klebsiella pneumoniae (9.9% vs2.8% p = 0.001) and Pseudomonas aeruginosa (2.2% vs 0.9% p = 0.034) growth was significantly higher in the HIPEC group. Conclusions: It has been found that HIPEC application not only increases the infection rates but also expands the potential pathogenspectrum. Prediction of possible pathogens responsible for postoperative infections may affect the choice of prophylactic andultimate treatment and so the risk of developing morbidity and mortality which may result from a possible septic progression, canbe minimized with an effective antimicrobial therapy.

PDF

___

1. Sugarbaker PH. Peritoneal surface oncology: Review of a personal experience with colorectal and appendiceal malignancy. Tech Coloproctol 2005;9:85 – 103.
2. Sugarbaker PH. Carcinomatosis from gastrointestinal cancer. Ann Med 2004; 36:9–22.
3. Bereder J, Glehen O, Habre J et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: a multiinstitutional study of 246 patients. J Clin Oncol 2009; 27 (15_suppl):5542.
4. Cummins KA, Russell GB, Votanopoulos KI et al. Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). J Gastrointest Oncol 2016;7:3.
5. Munoz-Zuluaga C, Sardi A, King MC et al. Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and hyperthermic intraperitoneal Chemotherapy. Ann Surg Oncol 2018;1- 9.
6. Manzanedo I, Pereira F, Perez-Viejo E et al. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer. Minerva Ginecol 2017;69:119-27.
7. Sugarbaker PH. Cytoreductive surgery and perioperative chemotherapy: Textbook and video atlas. Connecticut: Cine-Med Publishing;2013.
8. Glehen O, Kwiatkowski F, Sugarbaker PH et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284- 92.
9. Capone A, Valle M, Proietti F et al. Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Oncol 2007;96:507- 13.
10. Arslan NC, Sokmen S, Avkan-Oguz V et al. Infectious complications after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Surg Infections 2017;18:157-63.
11. Valle M, Federici O, Carboni F et al. Postoperative infections after cytoreductive surgery and HIPEC for peritoneal carcinomatosis: proposal and results from a prospective protocol study of prevention, surveillance and treatment. Eur J Surg Oncol (EJSO) 2014;40:950-6.
12. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 1982;5:649–55.
13. Sugarbaker PH. Peritoneal carcinomatosis: principle of management. Boston: Kluwer Academic;1996.
14. Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005;2:3.
15. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–13.
16. Cardi M, Sibio S, Di Marzo F et al. Prognostic factors influencing infectious complications after Cytoreductive Surgery and HIPEC: Results from a Tertiary Referral Center. Gastroenterol Res Pract 2019;2824073.
17. Newton AD, Bartlett EK, Karakousis GC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointestinal Oncol 2016;7:99–111.
18. Thong SY, Chia CS, Ng O et al. A review of 111 anaesthetic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Singapore Med J 22017;58:488–96.
19. Ahmed S, Oropello JM. Critical care issues in oncological surgery patients. Crit Care Clin 2010;26:93–106.
20. Waters PS, Smith AW, Fitzgerald E et al. Increased incidence of central venous catheter-related infection in patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Surg Infections 2019;20:465–71.
21. Alexiou K, Drikos I, Terzopoulou M et al. A prospective randomised trial of isolated pathogens of surgical site infections (SSI). Ann Medicine Surg 2012;21:25–9